Diabetes, Vol 41, Issue 10 1257-1266, Copyright © 1992 by American Diabetes Association

ARTICLES

Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome

A Dunaif, KR Segal, DR Shelley, G Green, A Dobrjansky and T Licholai
Department of Medicine, Mount Sinai School of Medicine, City University of New York, New York.

Women with PCO have a unique but poorly characterized disorder of insulin action. Obese (n = 16) and nonobese (n = 14) PCO women and age- and weight-matched normal, nondiabetic ovulatory women (obese, n = 15; nonobese, n = 17) had insulin action determined in vivo with sequential multiple insulin dose euglycemic clamps and in isolated abdominal adipocytes to clarify the mechanisms of insulin resistance. PCO resulted in significant increases in the ED50 insulin for glucose utilization in vivo (P less than 0.001) and in adipocytes (P less than 0.01), without significant changes in adipocyte insulin-binding sites. PCO also resulted in significant decreases in maximal insulin-stimulated rates of glucose utilization in vivo (P less than 0.01) and in adipocytes (P less than 0.01). Obesity resulted in smaller decreases in insulin sensitivity than PCO (ED50 insulin, P less than 0.001 in vivo and P less than 0.05 in adipocytes), but greater decreases in insulin responsiveness (Vmax, P less than 0.001 in vivo and in adipocytes). The ED50 insulin for suppression of HGP was increased only in obese PCO women (P less than 0.001), and the interactions between PCO and obesity on this parameter were statistically significant. No significant correlations between androgen or estrogen levels and adipocyte insulin binding or action were found. Because insulin binding was not changed, we conclude that the major lesion causing insulin resistance in PCO is a striking decrease in insulin sensitivity secondary to a defect in the insulin receptor and/or postreceptor signal transduction. PCO also is associated with modest but significant decreases in glucose transport. These defects in insulin action appear to represent intrinsic abnormalities that are independent of obesity, metabolic derangements, body fat topography, and sex hormone levels. Conversely, changes in hepatic insulin sensitivity appear to be acquired with obesity.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Gagnon and J.-P. Baillargeon Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome Can. Med. Assoc. J., March 27, 2007; 176(7): 933 - 938. [Abstract] [Full Text] [PDF]

				A Corbould Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women J. Endocrinol., March 1, 2007; 192(3): 585 - 594. [Abstract] [Full Text] [PDF]

				A. Corbould, H. Zhao, S. Mirzoeva, F. Aird, and A. Dunaif Enhanced Mitogenic Signaling in Skeletal Muscle of Women With Polycystic Ovary Syndrome Diabetes, March 1, 2006; 55(3): 751 - 759. [Abstract] [Full Text] [PDF]

				E. Lystedt, H. Westergren, J. Brynhildsen, L. Lindh-Astrand, J. Gustavsson, F. H Nystrom, M. Hammar, and P. Stralfors Subcutaneous adipocytes from obese hyperinsulinemic women with polycystic ovary syndrome exhibit normal insulin sensitivity but reduced maximal insulin responsiveness Eur. J. Endocrinol., December 1, 2005; 153(6): 831 - 835. [Abstract] [Full Text] [PDF]

				M. Urbanek, A. Woodroffe, K. G. Ewens, E. Diamanti-Kandarakis, R. S. Legro, J. F. Strauss III, A. Dunaif, and R. S. Spielman Candidate Gene Region for Polycystic Ovary Syndrome on Chromosome 19p13.2 J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6623 - 6629. [Abstract] [Full Text] [PDF]

				K. Lakhani, A. Leonard, A.M. Seifalian, and P. Hardiman Microvascular dysfunction in women with polycystic ovary syndrome Hum. Reprod., November 1, 2005; 20(11): 3219 - 3224. [Abstract] [Full Text] [PDF]

				S. Sam, R. S. Legro, R. Bentley-Lewis, and A. Dunaif Dyslipidemia and Metabolic Syndrome in the Sisters of Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4797 - 4802. [Abstract] [Full Text] [PDF]

				M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390. [Abstract] [Full Text] [PDF]

				G. Gennarelli, V. Rovei, R. F. Novi, J. Holte, F. Bongioanni, A. Revelli, G. Pacini, P. Cavallo-Perin, and M. Massobrio Preserved Insulin Sensitivity and {beta}-Cell Activity, but Decreased Glucose Effectiveness in Normal-Weight Women with the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3381 - 3386. [Abstract] [Full Text] [PDF]

				R. S. Legro, C. L. Gnatuk, A. R. Kunselman, and A. Dunaif Changes in Glucose Tolerance over Time in Women with Polycystic Ovary Syndrome: A Controlled Study J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3236 - 3242. [Abstract] [Full Text] [PDF]

				J. Vrbikova and D. Cibula Combined oral contraceptives in the treatment of polycystic ovary syndrome Hum. Reprod. Update, May 1, 2005; 11(3): 277 - 291. [Abstract] [Full Text] [PDF]

				A. Corbould, Y.-B. Kim, J. F. Youngren, C. Pender, B. B. Kahn, A. Lee, and A. Dunaif Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling Am J Physiol Endocrinol Metab, May 1, 2005; 288(5): E1047 - E1054. [Abstract] [Full Text] [PDF]

				T. Apridonidze, P. A. Essah, M. J. Iuorno, and J. E. Nestler Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 1929 - 1935. [Abstract] [Full Text] [PDF]

				V. Sepilian and M. Nagamani Effects of Rosiglitazone in Obese Women with Polycystic Ovary Syndrome and Severe Insulin Resistance J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 60 - 65. [Abstract] [Full Text] [PDF]

				E. O. Talbott, J. V. Zborowski, M. Y. Boudreaux, K. P. McHugh-Pemu, K. Sutton-Tyrrell, and D. S. Guzick The Relationship between C-Reactive Protein and Carotid Intima-Media Wall Thickness in Middle-Aged Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6061 - 6067. [Abstract] [Full Text] [PDF]

				H-W. Yen, A.J. Jakimiuk, I. Munir, and D.A. Magoffin Selective alterations in insulin receptor substrates-1, -2 and -4 in theca but not granulosa cells from polycystic ovaries Mol. Hum. Reprod., July 1, 2004; 10(7): 473 - 479. [Abstract] [Full Text] [PDF]

				S.B. Kjotrod, V. von During, and S.M. Carlsen Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study Hum. Reprod., June 1, 2004; 19(6): 1315 - 1322. [Abstract] [Full Text] [PDF]

				D. Cibula Is insulin resistance an essential component of PCOS?: The influence of confounding factors Hum. Reprod., April 1, 2004; 19(4): 757 - 759. [Abstract] [Full Text] [PDF]

				D. J. Jakubowicz, P. A. Essah, M. Seppala, S. Jakubowicz, J.-P. Baillargeon, R. Koistinen, and J. E. Nestler Reduced Serum Glycodelin and Insulin-Like Growth Factor-Binding Protein-1 in Women with Polycystic Ovary Syndrome during First Trimester of Pregnancy J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 833 - 839. [Abstract] [Full Text] [PDF]

				I. Munir, H.-W. Yen, D. H. Geller, D. Torbati, R. M. Bierden, S. R. Weitsman, S. K. Agarwal, and D. A. Magoffin Insulin Augmentation of 17{alpha}-Hydroxylase Activity Is Mediated by Phosphatidyl Inositol 3-Kinase But Not Extracellular Signal-Regulated Kinase-1/2 in Human Ovarian Theca Cells Endocrinology, January 1, 2004; 145(1): 175 - 183. [Abstract] [Full Text] [PDF]

				T. Tsilchorozidou, J. W. Honour, and G. S. Conway Altered Cortisol Metabolism in Polycystic Ovary Syndrome: Insulin Enhances 5{alpha}-Reduction But Not the Elevated Adrenal Steroid Production Rates J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5907 - 5913. [Abstract] [Full Text] [PDF]

				D. Romualdi, M. Guido, M. Ciampelli, M. Giuliani, F. Leoni, C. Perri, and A. Lanzone Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome Hum. Reprod., June 1, 2003; 18(6): 1210 - 1218. [Abstract] [Full Text] [PDF]

				E. Diamanti-Kandarakis, J.-P. Baillargeon, M. J. Iuorno, D. J. Jakubowicz, and J. E. Nestler A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1927 - 1932. [Full Text] [PDF]

				M. Schachter, A. Raziel, S. Friedler, D. Strassburger, O. Bern, and R. Ron-El Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine Hum. Reprod., April 1, 2003; 18(4): 721 - 727. [Abstract] [Full Text] [PDF]

				Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Diabetes Care, January 1, 2003; 26(90001): s5 - 20. [Full Text] [PDF]

				D. Cibula, J. Skrha, M. Hill, M. Fanta, L. Haakova, J. VrbIkova, and J. Zivny Prediction of Insulin Sensitivity in Nonobese Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5821 - 5825. [Abstract] [Full Text] [PDF]

				L. A. Stadtmauer, B. C. Wong, and S. Oehninger Should patients with polycystic ovary syndrome be treated with metformin?: Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction Hum. Reprod., December 1, 2002; 17(12): 3016 - 3026. [Abstract] [Full Text] [PDF]

				T. Bagis, A. Gokcel, H. B. Zeyneloglu, E. Tarim, E. B. Kilicdag, and B. Haydardedeoglu The Effects of Short-Term Medroxyprogesterone Acetate and Micronized Progesterone on Glucose Metabolism and Lipid Profiles in Patients with Polycystic Ovary Syndrome: A Prospective Randomized Study J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4536 - 4540. [Abstract] [Full Text] [PDF]

				R. Azziz Polycystic Ovary Syndrome, Insulin Resistance, and Molecular Defects of Insulin Signaling J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4085 - 4087. [Full Text] [PDF]

				M. Li, J. F. Youngren, A. Dunaif, I. D. Goldfine, B. A. Maddux, B. B. Zhang, and J. L. Evans Decreased Insulin Receptor (IR) Autophosphorylation in Fibroblasts from Patients with PCOS: Effects of Serine Kinase Inhibitors and IR Activators J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4088 - 4093. [Abstract] [Full Text] [PDF]

				J. Vrbikova, B. Bendlova, M. Hill, M. Vankova, K. Vondra, and L. Starka Insulin Sensitivity and {beta}-Cell Function in Women With Polycystic Ovary Syndrome Diabetes Care, July 1, 2002; 25(7): 1217 - 1222. [Abstract] [Full Text] [PDF]

				D. Cibula, M. Fanta, M. Hill, G. Sindelka, J. Skrha, and J. Zivny Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin Hum. Reprod., January 1, 2002; 17(1): 76 - 82. [Abstract] [Full Text] [PDF]

				M. M. Sandqvist, J. W. Eriksson, and P.-A. E. Jansson Increased Lactate Release per Fat Cell in Normoglycemic First-Degree Relatives of Individuals With Type 2 Diabetes Diabetes, October 1, 2001; 50(10): 2344 - 2348. [Abstract] [Full Text]

				A. Dunaif, X. Wu, A. Lee, and E. Diamanti-Kandarakis Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS) Am J Physiol Endocrinol Metab, August 1, 2001; 281(2): E392 - E399. [Abstract] [Full Text] [PDF]

				R. M. Koivunen, J. Juutinen, I. Vauhkonen, L. C. Morin-Papunen, A. Ruokonen, and J. S. Tapanainen Metabolic and Steroidogenic Alterations Related to Increased Frequency of Polycystic Ovaries in Women with a History of Gestational Diabetes J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2591 - 2599. [Abstract] [Full Text] [PDF]

				D. J. Jakubowicz, M. Seppälä, S. Jakubowicz, O. Rodriguez-Armas, A. Rivas-Santiago, H. Koistinen, R. Koistinen, and J. E. Nestler Insulin Reduction with Metformin Increases Luteal Phase Serum Glycodelin and Insulin-Like Growth Factor-Binding Protein 1 Concentrations and Enhances Uterine Vascularity and Blood Flow in the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1126 - 1133. [Abstract] [Full Text]

				P. J. Marsden, A. P. Murdoch, and R. Taylor Adipocyte insulin action in hypogonadotrophic hypogonadism Hum. Reprod., August 1, 2000; 15(8): 1672 - 1678. [Abstract] [Full Text] [PDF]

				L. C. Morin-Papunen, I. Vauhkonen, R. M. Koivunen, A. Ruokonen, and J. S. Tapanainen Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome Hum. Reprod., June 1, 2000; 15(6): 1266 - 1274. [Abstract] [Full Text] [PDF]

				C.-B. Book and A. Dunaif Selective Insulin Resistance in the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3110 - 3116. [Abstract] [Full Text]

				P. J.Marsden, A. P. Murdoch, and R. Taylor Adipocyte insulin action following ovulation in polycystic ovarian syndrome Hum. Reprod., September 1, 1999; 14(9): 2216 - 2222. [Abstract] [Full Text] [PDF]

				L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice The Insulin-Related Ovarian Regulatory System in Health and Disease Endocr. Rev., August 1, 1999; 20(4): 535 - 582. [Abstract] [Full Text] [PDF]

				K. Odunsi and K. K. Kidd A paradigm for finding genes for a complex human trait: Polycystic ovary syndrome and follistatin PNAS, July 20, 1999; 96(15): 8315 - 8317. [Full Text] [PDF]

				M. Urbanek, R. S. Legro, D. A. Driscoll, R. Azziz, D. A. Ehrmann, R. J. Norman, J. F. Strauss III, R. S. Spielman, and A. Dunaif Thirty-seven candidate genes for polycystic ovary syndrome: Strongest evidence for linkage is with follistatin PNAS, July 20, 1999; 96(15): 8573 - 8578. [Abstract] [Full Text] [PDF]

				A. Cagnacci, A.M. Paoletti, S. Arangino, G.B. Melis, and A. Volpe Effect of ovarian suppression on glucose metabolism of young lean women with and without ovarian hyperandrogenism Hum. Reprod., April 1, 1999; 14(4): 893 - 897. [Abstract] [Full Text] [PDF]

				A.M. Fulghesu, F. Cucinelli, V. Pavone, F. Murgia, M. Guido, A. Caruso, S. Mancuso, and A. Lanzone Changes in luteinizing hormone and insulin secretion in polycystic ovarian syndrome Hum. Reprod., March 1, 1999; 14(3): 611 - 617. [Abstract] [Full Text] [PDF]

				R. S. Legro, A. R. Kunselman, W. C. Dodson, and A. Dunaif Prevalence and Predictors of Risk for Type 2 Diabetes Mellitus and Impaired Glucose Tolerance in Polycystic Ovary Syndrome: A Prospective, Controlled Study in 254 Affected Women J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 165 - 169. [Abstract] [Full Text]

				R. S. Legro, D. Finegood, and A. Dunaif A Fasting Glucose to Insulin Ratio Is a Useful Measure of Insulin Sensitivity in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2694 - 2698. [Abstract] [Full Text]

				A. Dunaif Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis Endocr. Rev., December 1, 1997; 18(6): 774 - 800. [Abstract] [Full Text]

				D. A. Ehrmann, D. J. Schneider, B. E. Sobel, M. K. Cavaghan, J. Imperial, R. L. Rosenfield, and K. S. Polonsky Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2108 - 2116. [Abstract] [Full Text] [PDF]

				C. S. Mantzoros, A. Dunaif, and J. S. Flier Leptin Concentrations in the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1687 - 1691. [Abstract] [Full Text] [PDF]

				G. A. Laughlin, A. J. Morales, and S. S. C. Yen Serum Leptin Levels in Women with Polycystic Ovary Syndrome: The Role of Insulin Resistance/ Hyperinsulinemia J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1692 - 1696. [Abstract] [Full Text] [PDF]

				T. P. Ciaraldi, A. J. Morales, M. G. Hickman, R. Odom-Ford, J. M. Olefsky, and S. S. C. Yen Cellular Insulin Resistance in Adipocytes from Obese Polycystic Ovary Syndrome Subjects Involves Adenosine Modulation of Insulin Sensitivity J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1421 - 1425. [Abstract] [Full Text] [PDF]

				D. J. Jakubowicz and J. E. Nestler 17{alpha}-Hydroxyprogesterone Responses to Leuprolide and Serum Androgens in Obese Women with and without Polycystic Ovary Syndrome after Dietary Weight Loss J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 556 - 560. [Abstract] [Full Text] [PDF]

				R. D. Utiger Insulin and the Polycystic Ovary Syndrome N. Engl. J. Med., August 29, 1996; 335(9): 657 - 658. [Full Text]

				S. Franks Polycystic Ovary Syndrome N. Engl. J. Med., September 28, 1995; 333(13): 853 - 861. [Full Text] [PDF]